首頁 > 市場調查報告書 > 製藥

婦科治療

功能性子宮出血市場規模、佔有率和成長分析：按適應症、治療類型、藥物類別、給藥途徑、年齡層、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2102243

功能性子宮出血市場規模、佔有率和成長分析：按適應症、治療類型、藥物類別、給藥途徑、年齡層、最終用戶和地區分類－2026-2033年產業預測

Dysfunctional Uterine Bleeding Market Size, Share, and Growth Analysis, By Indication, By Treatment Type, By Drug Class, By Route of Administration, By Age Group, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年07月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球功能性子宮出血市場價值為 38.2 億美元，預計到 2033 年將從 2025 年的 39.9 億美元成長至 341.1 億美元，預測期（2026-2033 年）複合年成長率為 4.5%。

全球功能性子宮出血市場正經歷顯著成長，其主要促進因素包括荷爾蒙失衡導致的異常月經出血盛行率上升、肥胖率增加以及女性人口老化。此市場涵蓋多種治療方案，包括氨甲環酸和levonorgestrel子宮內避孕系統（LERS）等藥物，以及子宮鏡消融設備和影像解決方案等外科器械。如果出血無法妥善控制，可能導致貧血和醫療成本增加，對全球生產力產生負面影響。此外，隨著醫療機構尋求縮短住院時間和降低治療成本的方法，微創門診手術的普及也促進了市場擴張。射頻消融術和等離子輔助子宮內膜切除術等技術正逐漸被患者接受，尤其是在那些優先考慮成本效益型醫療解決方案的保險報銷模式的地區。

全球功能性子宮出血市場按適應症、治療方法、藥物類別、給藥途徑、年齡層、最終用戶、分銷管道和地區進行細分。依適應症分類，市場分為排卵性功能性子宮出血（排卵性異常子宮出血，Ovulatory AUB）和無排卵性功能性子宮出血（AUB）。依治療方法分類，市場分為荷爾蒙療法、非荷爾蒙療法和手術治療。依藥物類別分類，市場分為複方口服避孕藥（COCs）、黃體素、促性腺激素分泌釋放激素（GnRH）促效劑和拮抗劑、非類固醇消炎劑（NSAIDs）、抗纖溶藥物和其他藥物。依給藥途徑分類，市場分為口服、注射、子宮內給藥和其他給藥途徑。依年齡層別分類，市場分為青春期女性、育齡女性和閉經女性。根據最終用戶，市場可細分為醫院、婦科診所、門診手術中心（ASC）和其他機構。按分銷管道分類，市場可分為醫院藥房、零售藥房和線上藥房。依地區分類，市場可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球功能性子宮出血市場成長要素

由於公共衛生工作的加強以及旨在提高女性對異常子宮出血認知的社交媒體宣傳活動日益廣泛，全球功能性子宮出血市場正經歷顯著成長。隨著認知度的提高，越來越多的女性主動尋求醫療協助，從而實現了早期診斷，並對有效治療方案的需求也隨之增加。這種積極主動的態度不僅擴大了製藥公司和醫療設備製造商的基本客群，也促使醫療專業人員遵循實證醫學的診療方案。反過來，這又促使處方箋增加，並提高了醫療機構採用創新療法的意願。

全球功能性子宮出血市場的限制因素

先進的子宮治療醫療設備高成本，為醫院和診所帶來了巨大挑戰，尤其是在預算緊張的醫療體系下。在採購部門優先考慮成本控制的環境下，新技術的採用往往會被推遲，而成本較低的舊式替代方案則更受青睞。這種經濟障礙阻礙了市場滲透，減緩了銷售成長，並使製造商難以實現規模經濟。因此，即使先進的解決方案能夠帶來顯著的臨床益處，整體市場成長似乎也受到阻礙。此外，醫療機構可能會要求折扣，這可能會進一步延遲創新療法的普及，並延長其應用週期。

功能性子宮出血市場的全球趨勢

由於創新型微創療法的出現，全球功能性子宮出血市場正經歷變革性的轉變。子宮鏡手術和射頻消融術等技術因其縮短恢復時間、降低併發症發生率和保留生育能力等優勢，正迅速成為標準化的治療方法。為了滿足日益成長的病患需求，醫療機構正在建造專門的手術室，醫療設備製造商也在加速產品研發。教育機構也順應這些趨勢，加快技能培訓，並在全球成熟和新興的醫療保健體系中拓展市場管道。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Bayer AG
Pfizer Inc
AbbVie Inc
Myovant Sciences Ltd
Theramex
Organon & Co
Teva Pharmaceutical Industries Ltd
Viatris Inc
Sandoz International GmbH
Lupin Limited
Cipla Limited
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Medtronic plc
Boston Scientific Corporation
Hologic Inc
CooperCompanies Inc
Stryker Corporation
Cook Medical LLC
Merit Medical Systems Inc

結論與建議

簡介目錄

Product Code: SQMIG35I3347

Global Dysfunctional Uterine Bleeding Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 3.99 Billion in 2025 to USD 34.11 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The global market for dysfunctional uterine bleeding is experiencing significant growth driven by the increasing prevalence of abnormal menstrual bleeding linked to hormonal imbalances, rising obesity rates, and an older female demographic. This market encompasses a range of therapeutic options, including medications like tranexamic acid and levonorgestrel-releasing intrauterine systems, alongside surgical devices such as hysteroscopic ablation tools and diagnostic imaging solutions. Unmanaged bleeding can lead to anemia and heightened healthcare costs, affecting productivity worldwide. The shift towards outpatient minimally invasive procedures also contributes to market expansion, as healthcare providers seek methods to reduce hospital stay durations and procedural expenses. Techniques like radiofrequency ablation and plasma-based endometrial resection promote patient adoption, especially where reimbursement models favor cost-effective care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dysfunctional Uterine Bleeding market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dysfunctional Uterine Bleeding Market Segments Analysis

The global dysfunctional uterine bleeding market is segmented by indication, treatment type, drug class, route of administration, age group, end user, distribution channel and region. Based on indication, the market is segmented into Ovulatory Dysfunctional Uterine Bleeding (Ovulatory AUB) and Anovulatory Dysfunctional Uterine Bleeding (Anovulatory AUB). Based on treatment type, the market is segmented into Hormonal Therapy, Non-Hormonal Therapy and Surgical Treatment. Based on drug class, the market is segmented into Combined Oral Contraceptives (COCs), Progestins, Gonadotropin-Releasing Hormone (GnRH) Agonists & Antagonists, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Antifibrinolytics and Others. Based on route of administration, the market is segmented into Oral, Injectable, Intrauterine and Others. Based on age group, the market is segmented into Adolescents, Reproductive Age Women and Perimenopausal Women. Based on end user, the market is segmented into Hospitals, Specialty Gynecology Clinics, Ambulatory Surgical Centers (ASCs) and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dysfunctional Uterine Bleeding Market

The global market for dysfunctional uterine bleeding is experiencing significant expansion due to heightened public health initiatives and extensive social media engagement aimed at educating women about abnormal uterine bleeding. As awareness increases, many women become more proactive in seeking medical advice for their symptoms, leading to earlier diagnoses and a demand for effective treatments. This proactive approach not only broadens the customer base for pharmaceutical companies and device manufacturers but also encourages healthcare providers to follow evidence-based management protocols. Consequently, this results in an uptick in prescriptions and a greater willingness to explore innovative therapeutic solutions within the healthcare landscape.

Restraints in the Global Dysfunctional Uterine Bleeding Market

The high cost associated with advanced uterine treatment devices presents a significant challenge for hospitals and clinics, particularly within budget-conscious healthcare systems. In environments where procurement teams prioritize cost control, the adoption of newer technologies may be delayed, leading to a preference for older, lower-cost alternatives. This financial barrier hinders market penetration and slows sales growth, complicating efforts for manufacturers to achieve economies of scale. Consequently, even when advanced solutions offer substantial clinical benefits, overall market growth appears impeded. Additionally, providers may seek discounts, further prolonging access to innovative treatments and extending timelines for implementation.

Market Trends of the Global Dysfunctional Uterine Bleeding Market

The Global Dysfunctional Uterine Bleeding market is witnessing a transformative shift driven by the rise of innovative minimally invasive therapies. Techniques such as hysteroscopic procedures and radiofrequency ablation are rapidly becoming standard in treatment regimens due to their advantages of reduced recovery time, lower complication rates, and better preservation of fertility. In response to increasing patient demand, healthcare facilities are increasingly developing specialized procedure suites, while device manufacturers are accelerating their product developments. This trend is prompting educational institutions to adapt, enabling faster skill acquisition and broadening the market's accessibility in both established and emerging healthcare systems worldwide.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Dysfunctional Uterine Bleeding Market Size by Indication & CAGR (2026-2033)

Market Overview
Ovulatory Dysfunctional Uterine Bleeding (Ovulatory AUB)
Anovulatory Dysfunctional Uterine Bleeding (Anovulatory AUB)

Global Dysfunctional Uterine Bleeding Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Hormonal Therapy
Non-Hormonal Therapy
Surgical Treatment

Global Dysfunctional Uterine Bleeding Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Combined Oral Contraceptives (COCs)
Progestins
Gonadotropin-Releasing Hormone (GnRH) Agonists & Antagonists
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Antifibrinolytics
Others

Global Dysfunctional Uterine Bleeding Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable
Intrauterine
Others

Global Dysfunctional Uterine Bleeding Market Size by Age Group & CAGR (2026-2033)

Market Overview
Adolescents
Reproductive Age Women
Perimenopausal Women

Global Dysfunctional Uterine Bleeding Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Gynecology Clinics
Ambulatory Surgical Centers (ASCs)
Others

Global Dysfunctional Uterine Bleeding Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Dysfunctional Uterine Bleeding Market Size & CAGR (2026-2033)

North America (Indication, Treatment Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel)
- US
- Canada
Europe (Indication, Treatment Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Treatment Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Treatment Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Treatment Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myovant Sciences Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theramex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr Reddy's Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CooperCompanies Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stryker Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cook Medical LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merit Medical Systems Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments